GlobeNewswire

SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
05/11/2026
Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026 Received FDA Fast [...]
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
05/11/2026
RESET-Myositis ® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data [...]
AVITA Medical Announces National Medicare Physician Payment Framework and Simplified Billing Codes for RECELL Procedures in 2027
05/11/2026
CMS finalizes nationally published physician valuations; CMS’s four-code structure simplifies procedure reporting beginning January 1, 2027 VALENCIA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. ( [...]
Vericel Reports Third Quarter 2026 Financial Results and Raises Full-Year Financial Guidance
05/11/2026
Total Revenue Growth of 26% to $85.4 Million Net Income Increased 179% to $14.2 Million Adjusted EBITDA Margin of 30% Raised Full-Year Revenue Guidance to $344 to $346 Million and Adjusted EBITDA Margin Guidance to 28% [...]
Tangram annonce la présentation orale des données précliniques sur le TGM-148, mettant en évidence son mécanisme d’action dépendant du contexte, à l’occasion du congrès annuel 2026 de l’American Society of Hematology (ASH)
05/11/2026
Le TGM-148 stimule la génération de thrombine dans un contexte d’altération de l’hémostase Aucun signe de risque thrombotique n’a été observé lors d’une étude toxicologique à doses répétées menée chez des primates non [...]
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
05/11/2026
On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple [...]
Filana Therapeutics Reports Q3 2026 Financial Results and Provides Business Update
05/11/2026
– Patient screening in Phase 2a study of simufilam in TSC-related epilepsy expected to begin by Q1 2027, following recent lift of FDA clinical hold – Recent publication in Cells 1 provides new insights into simufilam’s [...]
electroCore to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
05/11/2026
ROCKAWAY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Canaccord [...]
Forward Therapeutics Announces U.S. FDA IND Clearance to Initiate Phase 2 Study of FT2109 in Psoriatic Arthritis
05/11/2026
BOSTON, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Forward Therapeutics, Inc. (“Forward” or the “Company”), a clinical-stage biotechnology company developing oral small molecule therapies for inflammation-driven diseases, today [...]
Processa Pharmaceuticals to Participate in Upcoming Investor Conferences
05/11/2026
VERO BEACH, FL, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company advancing differentiated therapeutic programs for [...]
Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences in November
05/11/2026
NORWOOD, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP), a clinical-stage company focused on oncology and obesity, today announced that Yuval Cohen, Ph.D., Chief Executive [...]
Galectin Therapeutics Presents New Analyses on Noninvasive Prediction of Variceal Development from its Belapectin Development Program at AASLD Liver Meeting 2026
05/11/2026
Galectin Therapeutics will present new clinical findings at American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Denver. These results will be covered in one oral presentation and two posters [...]
Immutep Announces Upcoming Poster Presentations at CTOS 2026 and ESMO Immuno-Oncology & Advanced Therapies Congress 2026
05/11/2026
SYDNEY, AUSTRALIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage immunotherapy company targeting cancer and autoimmune diseases, today [...]
Altimmune to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026
05/11/2026
MORRISTOWN, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a biopharmaceutical company advancing pemvidutide, an investigational balanced 1:1 glucagon/GLP-1 receptor agonist, in serious liver [...]
Baird Medical and Alpmed Announce FDA 510(k) and EU CE Submissions for Irreversible Electroporation (IRE) System
05/11/2026
510(k) Application to U.S. Food and Drug Administration and Application for European Union Certification Submitted in Fourth Quarter 2026 NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Baird Medical Investment Holdings [...]
Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights
05/11/2026
– Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in hidradenitis [...]
PharmAla Signs Agreement and Initiates R&D with Corealis Pharma for GMP Manufacturing of its patented ALA-002 Drug Product
05/11/2026
TORONTO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. ("PharmAla" or the "Company") (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development and manufacturing of MDXX- [...]
Scribe Therapeutics to Participate in Upcoming Healthcare Investor Conferences
05/11/2026
ALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR [...]
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
05/11/2026
WEST CHESTER, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum